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Abstract 
 
Background— IgM natural antibodies bind oxidatively modified low-density lipoprotein 
(LDL) and apoptotic cells and have been implicated as important for protection from 
atherosclerosis. We have directly investigated the requirement for IgM by studying the 
effects of IgM deficiency in LDL receptor-deficient mice (Ldlr
−/−
). 
Methods and Results— Mice deficient in serum IgM (sIgM) or complement C1q were 
crossed with Ldlr
−/−
 mice and studied on both low (LF) and high fat (HF) semi-synthetic 
diets. On both diets, en face and aortic root atherosclerotic lesions in sIgM.Ldlr
−/−
 mice were 
substantially larger and more complex, with accelerated cholesterol crystal formation and 
increased smooth muscle cell content in aortic root lesions. Combined C1q and IgM 
deficiency had the same effect as IgM deficiency alone. Increased apoptosis was observed in 
aortic root lesions of both sIgM.Ldlr
−/−
 and C1qa.Ldlr
−/−
 mice. Since lesions were 
significantly larger in IgM deficient mice than in the absence of C1q, IgM protective 
mechanisms therefore appear to be partially independent of classical pathway activation and 
apoptotic cell clearance. Levels of IgG antibodies against copper-oxidised LDL were lower in 
high fat fed sIgM.Ldlr
−/−
 mice, suggesting compensatory consumption of IgG in the absence 
of IgM. 
Conclusions— This study provides direct evidence that IgM antibodies play a central role in 
protection against atherosclerosis. The mechanism appears to be at least partly independent of 
classical pathway complement activation by C1q. 
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Introduction 
 
Oxidative modifications of low-density lipoprotein (LDL) induce inflammatory responses 
that are key initial steps in the pathogenesis of atherosclerosis.
1
 Both innate and adaptive 
immune responses are thought to contribute to lesion development, with involvement of 
antibodies which recognise epitopes on oxidised LDL (oxLDL) among other targets.
2
 Both 
IgG and IgM autoantibodies to oxLDL can be readily detected in both humans and animal 
models of atherosclerosis, and in some studies antibody titres correlated with disease 
severity.
3-5
 IgM monoclonal antibodies reacting with oxLDL have been cloned from 
apolipoprotein E deficient (ApoE
−/−
) mice and some have been found to bind the 
phosphorylcholine (PC) headgroup of oxidatively modified phospholipids.
6-8
 The prototypic 
and best characterised of these, EO6, is identical in sequence to T15, a classical natural 
antibody known to recognise PC expressed as a capsular epitope on Streptococcus 
pneumoniae.
8
 
 
While initial studies focused on the detrimental effects of antibodies in atherosclerosis, 
evidence has accumulated suggesting that they may also have protective roles.
9
 Numerous 
studies have shown that immunisation with malondialdehyde-modified LDL (MDA-LDL) 
reduces atherosclerosis and is associated with robust T cell-dependent IgG anti-oxLDL 
responses.
10-12
 Immunisation of LDL receptor deficient (Ldlr
−/−
) or ApoE
−/−
 mice with 
Streptococcus pneumoniae or phosphorylcholine (PC)-conjugated keyhole limpet 
hemocyanin is also atheroprotective, in association with a rise in IgM anti-PC antibody 
titre.
13,14
 However, the precise roles of antibodies in active immunization experiments is 
difficult to interpret conclusively in view of the greater antibody titres achieved by active 
immunisation compared with those obtained spontaneously,
15
 as well as the use of adjuvants 
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and the effects of immunisation on other immunological parameters, such as regulatory T 
cells.
16
  
 
One mechanism by which IgM antibodies may contribute to protection against 
atherosclerosis is by facilitating the clearance of apoptotic material from developing lesions. 
Opsonisation of apoptotic cells with IgM is known to accelerate their non-inflammatory 
clearance by macrophages, and this process requires cooperation with complement C1q.
17
 We 
have recently shown that C1q deficiency in C1qa.Ldlr
−/−
 mice accelerates atherosclerosis.
18
 
Increased numbers of apoptotic cells were observed in atherosclerotic lesions, consistent with 
the concept that defective waste disposal leads to accumulation of cellular debris within 
plaques.
19-21
 
 
In the present study we sought to examine directly the contribution of IgM antibodies in 
atherogenesis by crossing Ldlr
−/−
 mice with mice deficient in serum IgM (sIgM
−/−
) through 
gene-targeted disruption of the secretory tail of immunoglobulin µ chain.
22
 Although unable 
to secrete IgM, sIgM
−/−
 B cells maintain membrane IgM expression, and have intact class 
switching and IgG production.
22
 We compared sIgM.Ldlr
−/−
 mice with C1qa.Ldlr
−/−
 mice 
and with triple deficient C1qa.sIgM.Ldlr
−/−
 mice to contrast the effect of IgM on 
atherogenesis with selective disruption of the classical pathway. 
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Methods 
 
Mice 
sIgM
−/−
 mice were generated as described previously,
22
 and crossed with Ldlr
−/−
 mice (both 
backcrossed 10 times on C57BL/6 background) to generate sIgM.Ldlr
−/−
 mice. sIgM.Ldlr
−/−
 
mice were further crossed with C1qa.Ldlr
−/−
 mice
18
 to create “triple knockout” 
C1qa.sIgM.Ldlr
−/−
 mice. From 10 to 22 weeks of age, experimental groups of female mice 
received either a high fat (HF) diet or a low fat (LF) semisynthetic reference diet (see 
Supplementary Methods for details). The following numbers of mice were used for LF and 
HF diets respectively: Ldlr
−/−
 (n=12, n=12), C1qa.Ldlr
−/−
 (n=12, n=15), sIgM.Ldlr
−/−
 (n=14, 
n=15) and C1qa.sIgM.Ldlr
−/−
 (n=10, n=9). The aortic root of one LF-fed C1qa.sIgM.Ldlr
−/−
 
mouse was damaged in processing and was not used for analysis. Animal care and procedures 
were conducted according to institutional guidelines, and mice were kept under specific 
pathogen-free conditions. Total serum cholesterol and triglycerides were measured using 
colorimetric enzymatic assays (Infinity, Alpha Labs, Eastleigh, UK). Lipoprotein profiles 
were generated by fast performance liquid chromatography (FPLC) on a Superose 6 size-
exclusion column. 
 
Atherosclerotic lesion analysis 
Mice were killed by CO2 inhalation and blood removed from the inferior vena cava. Using a 
cannula inserted in the left ventricle, hearts were perfused sequentially with Krebs-Henseleit 
buffer at 37°C for 5 minutes, 2% formalin for 5min, and 2mL of Sudan IV solution by direct 
slow injection over 5 minutes. Each aorta was microdissected to remove adventitial fat, cut 
open longitudinally, destained briefly in 80% ethanol and photographed. En face plaque 
quantification was performed using ImagePro software (Media Cybernetics, MD) by a single 
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operator blinded to group allocation. Aortic root cryosection, Oil red O staining and lesion 
quantification were performed as previously described.
18
 
 
Immunohistochemistry 
Aortic root frozen sections were stained using standard immunohistochemistry to identify the 
following cell types: macrophages (MOMA-2 rat mAb, Serotec), VSMC (alkaline 
phosphatase (AP)-conjugated anti-α-smooth muscle actin Ab, Sigma-Aldrich, Poole, UK), T 
cells (goat anti-mouse CD3ε Ab, Santa Cruz Biotechnology, Santa Cruz, CA). The presence 
of lesional deposition of C5b-9 (rabbit anti-human C5b-9 Ab, Calbiochem, Merck 
Biosciences, Darmstadt, Germany) was identified using the same technique, and quantified as 
percentage lesion area staining positive using ImagePro. Lesional C3 (FITC-conjugated goat 
anti-mouse C3 Ab, MP Biomedicals, Cambridge, UK) and IgG (FITC-conjugated goat anti-
mouse IgG Ab, Sigma-Aldrich) were identified using immunofluorescence and quantified as 
mean fluorescence intensity per pixel. 
 
Quantification of lesional apoptosis 
Apoptotic cells were detected using TUNEL (Roche, Welwyn Garden City, UK) on aortic 
root cryosections, following the manufacturer’s instructions. Randomised slides were 
quantified by a single operator blinded to group allocation, and assessed for number of 
TUNEL positive cells fitting morphological criteria for apoptosis, including cell shrinkage, 
nuclear condensation or fragmentation and expressed as percentage of lesional cells. 
 
Confocal microscopy 
For confocal microscopy,
18
 aortic root cryosections were double-immunostained for CD68 
(Alexafluor 488-conjugated anti-CD68 Ab, Molecular Probes, Invitrogen, Paisley, UK) and 
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IgM (biotin-conjugated mouse anti-mouse IgM
b
 mAb and biotin-conjugated mouse anti-
mouse IgM
a
, BD Pharmingen, Oxford, UK) secondarily labelled with Alexa 568-conjugated 
streptavidin (Molecular Probes), counterstained with TOPRO-3. 
 
Lipoprotein isolation and modification 
Human LDL (density 1.019-1.063g/mL) was isolated from plasma of healthy donors after 
overnight fasting by differential density ultracentrifugation,
23
 and modified with either 
freshly synthesized malondialdehyde (MDA) or CuSO4 to generate MDA-LDL and copper-
oxidised LDL (CuOxLDL) (see Supplementary Methods).
24
 
 
Serum autoantibody measurement and assessment of autoimmunity 
For the detection of anti-MDA-LDL
24
 and anti-CuOxLDL antibodies, non-irradiated 
microtiter plates (Greiner Bio-One, Stonehouse, UK) were coated overnight at 4°C with 
either 15µg/mL MDA-LDL, CuOxLDL or native LDL in a coating buffer of 100mM 
NaHCO3 and 1mg/mL Na2EDTA or with coating buffer alone to assess non-specific binding. 
After washing with PBS with 0.5% Tween-20, plates were blocked with 5% BSA. Sera 
diluted in PBS-Tween were applied. AP-conjugated anti-mouse IgG, IgM or IgG1 Abs 
(Southern Biotech, Birmingham AL) were used for detection and plates were developed with 
p-nitrophenol phosphate. As Ldlr
−/−
 mice on the C57BL/6 background produce IgG2c 
(equivalent to IgG2a
b
) antibodies, whereas sIgM.Ldlr
−/−
 mice (carrying a129-derived interval 
over the Ig gene region) produce IgG2a (equivalent to IgG2a
a
) (unpublished, M.Botto), to 
detect IgG2a and IgG2c anti-MDA-LDL or anti-CuOxLDL antibodies, we used an AP-
conjugated polyclonal goat anti-mouse IgG2a (Southern Biotech) with equal specificity for 
both mouse IgG2a and IgG2c over the detection range used (see Supplementary data). Anti-
single-stranded DNA, anti-dsDNA, anti-chromatin and anti-histone antibodies were assayed 
 8 
by ELISA.
25
 For anti-cardiolipin and anti-β2glycoprotein I antibody ELISA assays and 
scoring of renal histology for glomerulonephritis see Supplementary Methods. 
 
Statistical analysis 
Results were analysed using Graphpad Prism version 3.0 (Graphpad Software, San Diego 
CA). Where data were not normally distributed non-parametric statistical tests were used and 
results are expressed as median (interquartile range): to compare two groups Mann-Whitney 
test was used; to compare three or more groups Kruskal-Wallis test followed by Dunn’s post-
test was used. Normally distributed data was compared using unpaired two-tailed Student’s t-
test  with Bonferroni correction for multiple comparisons. 
 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
 9 
Results 
 
Localisation of IgM in plaques of Ldlr
−/−
 mice 
Confocal microscopy was used to examine IgM deposition within atherosclerotic plaques and 
localisation relative to macrophages. IgM was found within lesions following either low fat 
(LF) or high fat (HF) diets, particularly in the acellular core and with a reciprocal relationship 
to CD68-positive macrophages (Figure 1A). No IgM was detected within atherosclerotic 
lesions of sIgM.Ldlr
−/−
 mice, indicating detection specificity (Figure 1B). 
 
Accelerated atherosclerosis in serum IgM deficient mice 
No significant differences between all four mouse strains on either diet were noted in final 
body weight, total serum cholesterol or triglycerides (Supplementary Table 1), or lipoprotein 
FPLC profiles (not shown). Atherosclerotic plaque burden was quantified in sIgM.Ldlr
−/−
 
mice and compared with Ldlr
−/−
 control mice and with C1qa.Ldlr
−/−
 mice. On the LF diet, a 
hierarchy was apparent such that C1qa.Ldlr
−/−
 mice showed a moderate increase (2.8-fold) in 
atherosclerotic lesion area fraction at the aortic root (C1qa.Ldlr
−/−
, median 4.58% 
(interquartile range 1.42-8.44%), n=12 vs. Ldlr
−/−
, 1.64% (1.11-2.72%), n=12; P<0.05, using 
Kruskall-Wallis test with Dunn’s post-test), whereas both sIgM.Ldlr−/− and 
C1qa.sIgM.Ldlr
−/−
 mice demonstrated substantially increased lesion size of 6.1-fold and 4.1-
fold respectively (sIgM.Ldlr
−/−
 10.0% (4.96-12.9%), n=14; C1qa.sIgM.Ldlr
−/−
 6.76% (5.11-
10.4%), n=9; both P<0.001 vs. Ldlr
−/−
) (Figure 2A and 2B). On the HF diet (Figure 2A and 
2C), aortic root lesions in sIgM.Ldlr
−/−
 mice were 29% increased compared to Ldlr
−/−
 mice 
(sIgM.Ldlr
−/−
 35.8% (31.1-39.1%), n=15; Ldlr
−/−
 27.8% (24.0-30.5%), n=12; P<0.05) and 
33% increased in C1qa.sIgM.Ldlr
−/−
 mice (36.9% (33.5-39.9%), n=9; P<0.01). There was no 
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difference between C1qa.Ldlr
−/−
 (26.4% (20.7-31.8%), n=15, P=1.00) and Ldlr
−/−
 mice 
following the HF diet confirming our previously published data.
18
 
 
Whole aorta en face atherosclerotic lesion area mirrored the aortic root lesion data, showing a 
comparable hierarchy of effects of C1q and sIgM deficiency. On the LF diet C1qa.Ldlr
−/−
 
mice showed a moderate (although not statistically significant) increase of approximately 2.1-
fold in en face atherosclerotic lesion area compared to Ldlr
−/−
 mice (C1qa.Ldlr
−/−
 2.87% 
(1.71-3.56%), n=12 vs. Ldlr
−/−
 1.36% (0.73-1.72%), n=12; P=0.26) (Figure 3A and 3B). A 
substantially greater increase (~7-fold) in en face staining was evident in the sIgM.Ldlr
−/−
 
group compared to Ldlr
−/−
 controls, with an equal increase seen in C1qa.sIgM.Ldlr
−/−
 triple 
knockouts (sIgM.Ldlr
−/−
, 9.48% (5.36-10.9%), n=14; C1qa.sIgM.Ldlr
−/−
, 7.18% (4.79-
11.4%), n=10; both P<0.001 vs. Ldlr
−/−
). On the HF diet, a 66% increase in Sudan IV 
staining was still seen in the sIgM.Ldlr
−/−
 group compared to Ldlr
−/−
 controls (12.4% (8.48-
17.2%), n=15 vs. 7.49% (6.13-8.77%), n=12; P<0.05) (Figure 3C and 3D). 
C1qa.sIgM.Ldlr
−/−
 showed a similar level of en face atherosclerotic lesions (10.1% (7.88-
14.1%), n=9) as sIgM.Ldlr
−/−
 mice, while C1qa.Ldlr
−/−
 (5.23% (4.77-6.70%), n=15) were not 
statistically different to Ldlr
−/−
 mice (P=0.16). 
 
Increased lesion complexity in the absence of serum IgM 
Aortic root lesions in Ldlr
−/−
 mice fed the LF diet were largely fatty streaks, composed 
virtually entirely of macrophages. On both LF (Figure 4A) and HF (Figure 4B) diets, 
sIgM.Ldlr
−/−
 lesions showed a significant increase in population by vascular smooth muscle 
cells (VSMC), identified by positive staining for α-smooth muscle actin (LF diet: 
sIgM.Ldlr
−/−
 4.95% (1.80-7.87%), n=14 vs. Ldlr
−/−
 0.0% (0.0-2.29%), n=12; P=0.008; HF 
diet: sIgM.Ldlr
−/−
 19.7% (11.6-33.9%), n=15 vs. Ldlr
−/−
 6.73% (3.85-10.4%), n=12; 
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P=0.0004), with a reciprocal drop in macrophage content. On the HF diet, substantial 
numbers of sIgM.Ldlr
−/−
 aortic root sections demonstrated fibrous caps (Figure 4C). Even on 
the LF diet, cholesterol crystal deposition was noted in the aortic root lesions of sIgM.Ldlr
−/−
 
mice (Figure 4C), whereas there was no evidence of cholesterol crystal deposition in the LF 
fed Ldlr
−/−
 mice. There was no difference between sIgM.Ldlr
−/−
 and Ldlr
−/−
 in the proportion 
of lesional T lymphocytes (assessed with anti-CD3ε) on either diet (Figure 4A & B). Using 
immunofluorescence for IgG and C3, mean fluorescent intensity per pixel was quantified as 
an estimate of the density of lesional IgG and C3 deposition. There was no difference in the 
mean fluorescent intensity for IgG or C3 deposition in aortic root lesions between Ldlr
−/−
 and 
sIgM.Ldlr
−/−
 mice on either diet (Figure 4A, B and C), nor any difference in the level of 
lesional C5b-9 (not shown). 
 
Clearance of apoptotic cell debris in atherosclerotic lesions in the absence of IgM 
Lesional apoptosis in sIgM.Ldlr
−/−
 mice was at a level similar to that found in C1qa.Ldlr
−/−
, 
which were previously demonstrated to have impaired lesional apoptotic cell clearance.
18
 
Thus, using a combination of TUNEL staining and morphological identification, aortic root 
lesions of sIgM.Ldlr
−/−
 mice fed the LF diet contained increased numbers of apoptotic cells 
compared to Ldlr
−/−
 controls, reaching statistical significance when analysed by Mann-
Whitney test (P=0.047). However, using more stringent Kruskal-Wallis post-tests only 
C1qa.Ldlr
−/−
 mice showed increased numbers of apoptotic cells (P<0.01), and neither 
sIgM.Ldlr
−/−
 nor C1qa.sIgM.Ldlr
−/−
 mice reached significance, compared to Ldlr
−/−
 controls 
(Figure 5A and 5B). More apoptotic cells were detectable in Ldlr
−/−
 controls following the 
HF diet, such that differences between HF-fed groups were not significant (Figure 5C). 
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Autoantibody production in sIgM.Ldlr
−/−
 mice 
sIgM
−/−
 mice on a mixed C57BL/6×129 background have previously been reported to 
produce anti-double-stranded DNA (dsDNA) and aCL antibodies.
26
 However sIgM
−/−
 mice 
backcrossed for 10 generations on the C57BL/6 background do not produce autoantibodies 
(unpublished data, M. Botto). Serological tests were conducted to check for evidence of 
autoimmunity in sIgM.Ldlr
−/−
 mice. LF-fed sIgM.Ldlr
−/−
 mice showed low levels of IgG 
anti-single-stranded DNA (ssDNA) antibodies, which were not statistically different to levels 
in Ldlr
−/−
 mice (Table 1). However a significant increase in IgG anti-ssDNA antibodies was 
noted when sIgM.Ldlr
−/−
 mice were fed the HF diet compared to HF-fed Ldlr
−/−
 controls 
(P<0.001, Kruskal-Wallis post-test). Although raised, levels of anti-ssDNA antibodies in HF-
fed sIgM.Ldlr
−/−
 mice were low compared with 6 month old MRL/lpr mouse serum that was 
used as a standard (1000 ELISA units). Only HF-fed Ldlr
−/−
 mice showed modest titres of 
IgG anticardiolipin antibodies (aCL), while all other groups showed non-significant levels. 
Other autoantibodies, including antinuclear antibodies, anti-dsDNA, antichromatin and anti-
β2glycoprotein I antibodies were essentially undetectable in all experimental groups. There 
was no evidence of proteinuria or glomerulonephritis in any group (not shown). 
 
Changes in levels of IgG antibodies against MDA-LDL and CuOxLDL 
To examine whether IgM deficiency influences IgG antibody responses against oxidised LDL 
(oxLDL), titres of anti-MDA-LDL and anti-CuOxLDL antibodies were assayed in Ldlr
−/−
 
and sIgM.Ldlr
−/−
 mice at 22 weeks of age by ELISA. There was a significant increase in IgM 
and IgG antibodies to CuOxLDL, but not to MDA-LDL, in HF-fed versus LF-fed Ldlr
−/−
 
mice, and, as expected, IgM antibodies were not detected in sIgM.Ldlr
−/−
 sera (Figure 6). 
There were no significant differences in IgG anti-MDA-LDL or anti-CuOxLDL antibody titre 
in sIgM.Ldlr
−/−
 mice compared with Ldlr
−/−
 mice on the LF diet. However, there was a 
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significant reduction in IgG anti-CuOxLDL antibodies in sIgM.Ldlr
−/−
 mice fed a HF diet 
compared with HF-fed Ldlr
−/−
 mice. 
 Hypercholesterolaemia in ApoE
−/−
 mice has been shown to cause a Th1 to Th2 switch 
resulting in increased IgG1 anti-MDA-LDL antibody formation.
24
 To investigate whether 
increased atherosclerosis in sIgM.Ldlr
−/−
 mice was associated with an increased Th2 
response, IgG1 and IgG2a/2c isotypes were also assayed. For both isotypes generally no 
differences were seen between sIgM.Ldlr
−/−
 and Ldlr
−/−
 mice, with the exception of slightly 
lower IgG2a/2c anti-CuOxLDL antibodies observed in LF-fed sIgM.Ldlr
−/−
 mice (significant 
only at the lowest dilution). 
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Discussion 
In this paper, we have shown that Ldlr
−/−
 mice deficient in serum IgM display a substantial 
acceleration of atherosclerosis on both a LF and HF diet, with larger lesions, an increase in 
lesional cholesterol crystal formation and an increase in VSMC content consistent with 
fibrous cap formation. Overall, our data provide the first direct evidence that endogenous 
IgM natural antibodies are necessary for atheroprotection, and build on previous experimental 
studies on humoral immunity in mice that have shown reduction of atherosclerosis by (i) B 
cell rescue of splenectomised mice;
27
 (ii) administration of polyclonal human IgG;
28,29
 (iii) 
administration of a monoclonal human IgG1 antibody against MDA-LDL;
30,31
 and (iv) raising 
IgM anti-PC antibody levels by vaccination with pneumococci
13
 or PC conjugated to keyhole 
limpet hemocyanin.
14
 
 
One of the primary functions of IgM is to activate complement. Previous studies in mouse 
models have shown increased arterial lipid deposition and macrophage infiltration in mice 
with deficiency of C1q or C3, suggesting that complement has atheroprotective effects.
18,32,33
 
However, whilst C1q deficiency was associated with increased VSMC content in lesions,
18
 
the opposite was reported in C3 deficient mice,
32
 raising the possibility that different modes 
of complement activation may have distinct effects on atherogenesis. The direct comparison 
of sIgM.Ldlr
−/−
 mice with C1qa.Ldlr
−/−
 and triple “knockout” C1qa.sIgM.Ldlr−/− mice 
allowed us to gauge how much of the IgM-related atheroprotection was mechanistically 
linked to downstream classical pathway complement activation via C1q. As previously 
published, C1qa.Ldlr
−/−
 mice on the LF diet showed a modest increase in aortic root lesion 
size, but C1q deficiency had no detectable effect in mice fed a HF diet.
18
 The differences in 
this paper between sIgM.Ldlr
−/−
 and C1qa.Ldlr
−/−
 mice now demonstrate a hierarchy, with 
IgM playing a dominant role. Consistent with this, combined deficiency of C1q and sIgM 
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showed no difference in the level of atherosclerosis compared to IgM deficiency alone. It is 
possible that in the absence of C1q, IgM may bypass the classical pathway and instead 
activate the lectin pathway,
34
 as has been shown in ischaemia-reperfusion injury.
35
 However, 
in the sIgM.Ldlr
−/−
 mice we found no difference in the density of lesional C3 or C5b-9 
staining compared with the Ldlr
−/−
 mice, suggesting that at least part of the mechanism by 
which IgM exerts its protective effect in atherosclerosis is independent of complement 
activation in the arterial wall. 
 
Both C1q and IgM have been implicated as important recognition molecules mediating 
clearance of dying cells.
17,36
 We observed increased levels of apoptotic cells and TUNEL 
positive cellular debris within aortic root atherosclerotic plaques of sIgM.Ldlr
−/−
 mice, 
similar to those seen in C1qa.Ldlr
−/−
.
18
  Increased lesional apoptosis was not observed in 
C1qa.sIgM.Ldlr
−/−
 mice, raising the possibility of compensatory mechanisms occurring 
within the triple knock-outs. There was no difference in apoptotic cell numbers between the 
groups on the HF diet, primarily due to increased lesional apoptosis in Ldlr
−/−
 controls.  It is 
important to note that although defective clearance of cellular debris within atherosclerotic 
plaques may be a significant contributing factor to the increase in lesion size noted in 
sIgM.Ldlr
−/−
 and C1qa.Ldlr
−/−
 mice on the LF diet, increased numbers of lesional apoptotic 
cells may also be a function of lesion size.  Overall, the data on lesional apoptotic cells do not 
support a failure of apoptotic cell clearance being the only or even the major mechanism by 
which IgM deficiency accelerates atherosclerosis, and certainly do not account for the greater 
lesion size in sIgM.Ldlr
−/−
 compared to C1qa.Ldlr
−/−
 mice. 
 
Although deficiency of serum IgM has been shown to predispose to the development of anti-
dsDNA and aCL antibodies on certain murine genetic backgrounds,
26,37
 sIgM
−/−
 mice do not 
 16 
develop autoantibodies when fully backcrossed onto the C57BL/6 background (unpublished, 
M.Botto). Unexpectedly we observed that sIgM.Ldlr
−/−
 mice on the HF diet developed anti-
ssDNA autoantibodies, supporting previous observations that there is an interaction between 
hypercholesterolaemia and predisposition to lupus-like autoimmunity.
19
 Hence IgM 
deficiency enhances autoimmunity both in a strain-dependent and lipid-dependent manner. It 
should be noted however that the levels of anti-ssDNA in sIgM.Ldlr
−/−
 mice on the HF diet 
were low compared to those seen in classical lupus models (e.g. MRL/lpr), and no mice 
developed renal disease.  It therefore seems unlikely that lupus-like autoimmunity contributed 
significantly to the accelerated arterial disease we observed. 
 
The main purpose of measuring levels of IgG antibodies against MDA- and CuOxLDL was 
to check whether removal of IgM would result in a change in predominant IgG isotype or a 
compensatory increase in levels of IgG antibodies to these antigens.  There was no evidence 
in sIgM.Ldlr
−/−
 mice of a change in IgG isotype reflecting a Th1 to Th2 switch.
24
  
Paradoxically, there was a significant reduction in IgG antibodies against CuOxLDL in 
sIgM.Ldlr
−/−
 mice fed a HF diet compared with Ldlr
−/−
 mice.  Whilst theoretically this may 
be due to an idiosyncratic reduction in IgG synthesis related to IgM deficiency, class 
switching is thought to be relatively normal in sIgM
−/−
 mice.
22
 One plausible explanation is 
that the lower IgG CuOxLDL antibody level in HF-fed sIgM.Ldlr
−/−
 mice is due to depletion 
of IgG by oxLDL particles that would have bound IgM  in Ldlr
−/−
 mice. This raises the 
question as to what extent the protective effect of IgM is related to actions such as inhibition 
of uptake of oxLDL by macrophages within lesions,
7
 and how much is due to facilitating safe 
clearance of oxLDL from the circulation or other tissues. For example, IgM may well be 
important for opsonising circulating oxLDL particles and targeting them to the liver, which is 
known to be the major organ for circulating oxLDL uptake.
38
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Although mechanistic conclusions cannot be drawn from clinical studies relating antibody 
levels with disease, it is relevant that there have been reports showing inverse correlations 
between serum levels of IgM anti-oxLDL or anti-phosphorylcholine antibodies and 
progression of carotid atherosclerosis,
39-41
 as well as angiographically determined coronary 
artery disease.
42
 Taken together with the emerging experimental evidence in this and previous 
studies that IgM and IgG antibodies can be atheroprotective, there is therefore increasing 
rationale for therapeutic strategies aimed at boosting humoral immunity. Conversely, B cell 
depletion therapy using the anti-CD20 monoclonal antibody rituximab is increasingly used to 
treat autoimmune conditions including systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA). Up to 20% of patients with RA treated with repeated courses of B cell 
depletion develop abnormally low levels of sIgM, with less effect on serum IgG levels.
43
 It 
seems possible that repeated B cell depletion might increase cardiovascular risk due to 
preferential depletion of serum IgM, in a population already susceptible to cardiovascular 
complications.
44
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Figure Legends 
 
Figure 1. Deposition of IgM in atherosclerotic lesions. Confocal images of aortic root 
sections double-immunostained for CD68 (green) and IgM (red) and counterstained with 
TOPRO nuclear dye (blue). (A) Low power view of aortic root lesion from LF-fed Ldlr
−/−
 
mouse showing IgM deposition in the acellular base of the lesion and its relationship to 
lesional macrophages. (B) Low power view of similar lesion from LF-fed sIgM.Ldlr
−/−
 
mouse showing complete absence of IgM. 
 
Figure 2. Accelerated atherosclerotic lesion formation in aortic roots of sIgM deficient 
mice. (A) Representative sections from Ldlr
−/−
, C1qa.Ldlr
−/−
, sIgM.Ldlr
−/−
 and 
C1qa.sIgM.Ldlr
−/−
 mice stained with Oil Red O and haematoxylin. Scale bars 500µm. (B, C) 
Cross-sectional aortic root lesion area fraction (%) on (B) LF or (C) HF diet. Each point 
represents the mean of 5 sections per mouse, and bars show overall median. *P<0.05, 
**P<0.01, ***P<0.001 by Kruskal-Wallis test with Dunn’s post-test.  
 
Figure 3. Accelerated lesion formation in en face aorta preparations of sIgM deficient 
mice. (A, C) Representative Sudan IV-stained en face aorta preparations from Ldlr
−/−
, 
C1qa.Ldlr
−/−
, sIgM.Ldlr
−/−
 and C1qa.sIgM.Ldlr
−/−
 mice following 12 weeks of (A) LF or (C) 
HF diet. Scale bars 0.5mm. (B, D) Quantification of en face aorta lesion area expressed as % 
lesion area fraction on (B) LF or (D) HF diet, with bars showing the median. *P<0.05, 
**P<0.01, ***P<0.001 by Kruskal-Wallis test with Dunn’s post-test. 
 
Figure 4. Increased complexity of aortic root lesions in sIgM deficient mice. MOMA-2 
positive macrophages, α-smooth muscle actin positive VSMC and CD3+ T cells expressed as 
% of lesional cells on (A) low fat (Ldlr
−/−
 n=12, sIgM.Ldlr
−/−
 n=14) and (B) high fat diet 
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(Ldlr
−/−
 n=12, sIgM.Ldlr
−/−
 n=15). Density of aortic root lesion IgG and C3 deposition 
measured as mean fluorescence intensity per pixel on (A) low fat and (B) high fat diet (n 
numbers as before), expressed as relative fluorescence units (RFU) per pixel. Bars represent 
median, and statistical analysis was by Mann-Whitney test. (C) Representative 
photomicrographs of aortic root lesions showing cholesterol crystals under polarizing 
microscopy (age 22 wk, LF diet), smooth muscle fibrous cap formation (blue), lesional IgG 
and C3 deposition using fluorescence microscopy on HF diet in sIgM.Ldlr
−/−
 compared to 
Ldlr
−/−
 mice. Autofluorescence using a FITC-conjugated isotype control is shown below. 
Scale bars 100µm. 
 
Figure 5. Increased apoptosis in atherosclerotic lesions of LF-fed C1qa.Ldlr
−/−
, 
sIgM.Ldlr
−/−
 and C1qa.sIgM.Ldlr
−/−
 mice. (A) Representative photomicrographs of TUNEL 
staining (brown) from LF-fed mice, counterstained with haematoxylin, showing few 
apoptotic cells in Ldlr
−/−
 mice, but increased lesional apoptotic cells in C1qa.Ldlr
−/−
, 
sIgM.Ldlr
−/−
 and C1qa.sIgM.Ldlr
−/−
 mice. Scale bars 50µm. Quantification of lesional 
apoptotic cells on basis of TUNEL positive staining and morphological nuclear changes 
consistent with apoptosis on (B) LF diet and (C) HF diet, expressed as % of total lesional 
nuclei. Bars represent median. **P<0.01 by Kruskall-Wallis post-test. 
  
Figure 6. IgG and IgM anti-oxLDL antibodies in Ldlr
−/−
 and sIgM.Ldlr
−/−
 mice. Serial 
dilution curves showing titres of (A) anti-MDA-LDL and (B) anti-CuOxLDL antibodies in 
Ldlr
−/−
 and sIgM.Ldlr
−/−
 mice on low and high fat diets at 22 weeks of age. Non-specific 
binding to native LDL is shown at a single dilution. Error bars show SEM. †P<0.05 
sIgM.Ldlr
−/−
 (LF) vs. Ldlr
−/−
 (LF). **P<0.01 sIgM.Ldlr
−/−
 (HF) vs. Ldlr
−/−
 (HF). §P<0.05, 
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§§P<0.01, §§§P<0.001 Ldlr
−/−
 (LF) vs. Ldlr
−/−
 (HF). Statistical analysis by unpaired t-test 
with Bonferroni correction for multiple comparisons. 
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Table 1. Autoantibody profiles in Ldlr
−/−
 and sIgM.Ldlr
−/−
 mice at 22 weeks of age 
 
 LF diet HF diet 
 Ldlr
−/−
 
n=12 
sIgM.Ldlr
−/−
 
n=14 
Ldlr
−/−
 
n=12 
sIgM.Ldlr
−/−
 
n=15 
ssDNA 14.2 (10.5-24.66) 22.0 (16.2-37.8) 14.3 (4.70-29.3) 49.6 (26.7-87.9)* 
dsDNA 2.16 (1.67-4.22) 1.46 (1.10-5.35) 2.50 (1.62-3.44) 5.27 (3.08-9.12) 
Chromatin 9.98 (6.67-15.2) 11.5 (8.25-26.5) 17.1 (13.7-25.5) 16.1 (9.82-22.3) 
aCL 7.43 (0-43.7) 14.2 (0-44.7) 38.4 (0-75.1) 0 (0-18.3) 
β2GPI 4.84 (2.43-7.27) 1.96 (0.26-10.5) 3.74 (2.42-7.43) 4.21 (1.22-8.64) 
 
Serum IgG anti-single-stranded DNA (ssDNA), anti-dsDNA, anti-chromatin, anticardiolipin 
(aCL) and anti-β2glycoprotein I (β2GPI) antibody levels expressed as median (interquartile 
range) in arbitrary ELISA units, compared against a reference standard of pooled MRL/lpr 
mouse sera. *P<0.001 vs. HF-fed Ldlr
−/−
 (post-test following Kruskal-Wallis test) 
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
Diets 
In more detail the constituents of the high fat (HF) diet used were: 15% cocoa butter, 1% corn 
oil, 0.25% cholesterol, 40.5% sucrose, no cholic acid, total fat content 16% (Arieblok Diet 
W). The low fat (LF) semisynthetic reference diet contained: 54.3% glucose, 5% soya oil, no 
added cholesterol, total fat content 5.2% (Arieblok Reference Diet 4068.02). Both diets were 
purchased from Hope Farms, Woerden, Netherlands. 
 
Lipoprotein isolation 
Human LDL (density 1.019-1.063g/mL) was isolated from plasma of healthy donors after 
overnight fasting by differential density ultracentrifugation.1 Plasma was centrifuged at a 
density of 1.019g/mL at 53 000rpm for 16 hours at 5°C in a 70Ti fixed-angle rotor (Beckman 
Instruments, Inc.). The lower layer was adjusted to density 1.30g/mL, layered under KBr 
(density 1.006g/mL) and centrifuged in a 50Ti vertical rotor at 50 000rpm for 2½ hours at 
8°C. The LDL band was removed, adjusted to density 1.063g/mL with KBr and centrifuged 
at 43 000rpm in a SW50.1 rotor at 8°C. The purified LDL was gel filtered on PD-10 columns 
(Pharmacia Biotech AB, Uppsala, Sweden) to remove KBr and sterile filtered. Protein 
content was determined by nanospectrophotometry. The purified LDL was stored at 4°C in 
the presence of 1mmol/L Na2EDTA and used within 2 weeks. 
 
Modification of LDL 
Malondialdehyde (MDA) was synthesised by acid hydrolysis of malondialdehyde bis 
dimethylacetal (Sigma-Aldrich, Poole, UK).2,3 In summary, 96μL 4M HCl, 704μL 
malondialdehyde bis dimethylacetal was mixed with 3.2mL ddH2O and incubated for 10 
minutes at 37°C. The reaction was neutralised by adjusting the pH to 7.4 with 1M NaOH. 
LDL was gel filtered to remove EDTA and incubated with 0.5M MDA at a ratio of 100μL 
MDA/mg LDL for 3 hours at 37°C. To generate copper oxidised-LDL (CuOxLDL), LDL 
diluted in PBS to concentration of 1mg/mL was mixed with 10μM CuSO4 for 16 hours at 
37°C. After oxidation MDA-LDL or CuOxLDL was gel filtered to remove residual MDA or 
CuSO4. To limit further modification, Na2EDTA was added to a concentration of 2.7mmol/L. 
Both MDA-LDL and CuOxLDL were used immediately. Agarose gel electrophoresis 
(Paragon Lipokit, Beckman) confirmed consistent oxidative modification of LDL. 
 
Measurement of anticardiolipin and anti-β2glycoprotein I antibodies 
To measure anticardiolin (aCL) antibodies, non-irradiated plates were coated overnight at 
4°C with bovine cardiolipin in ethanol (1μg/well) and blocked with 10% adult bovine serum 
(ABS, Sigma-Aldrich). Serum samples were diluted 1:100 in 10% ABS. AP-conjugated anti-
mouse IgG antibody (Southern Biotech) diluted 1:1000 in 10% ABS was applied and plates 
were developed with p-nitrophenol phosphate. For the measurement of anti-β2glycoprotein I 
antibodies, 96 well polystyrene plates (NUNC Maxisorp) were coated overnight at 4°C with 
purified human β2glycoprotein I (Crystal Chem, IL) in borate buffered saline, then blocked 
with 2% BSA. After incubation with serum samples diluted in 2% BSA, AP-conjugated goat 
anti-mouse IgG antibody was applied and plates developed with p-nitrophenol phosphate. 
 
Renal analysis 
Urinalysis dipstick (Bayer) was used to screen for proteinuria and haematuria. Kidney 
portions were harvested at sacrifice prior to perfusion, processed in Bouin’s solution for 2 
hours, transferred to 70% ethanol, embedded in paraffin, stained with periodic acid-Schiff 
and scored for glomerulonephritis as previously described.4 
 
Specificity testing of antibody for both mouse IgG2a and IgG2c
A standard ELISA was set up to measure levels of IgG2a and IgG2c, using a goat anti-mouse 
Ig antibody (Southern Biotech) as the capture antibody. Serial dilutions of commercial mouse 
IgG2a standard (HOPC-1 clone, Southern Biotech) or IgG2c reference serum (serum pool from 
C57BL/6 mice, Bethyl Laboratories) of known concentrations were added. The secondary 
antibody (alkaline phosphatase-conjugated polyclonal goat anti-mouse IgG2a, Southern 
Biotech cat. 1080-40) being tested was added. The substrate pNPP was used and plates read 
at 405nm after 30mins. 
 
 
 
Supplemental Table 1. Baseline characteristics in Ldlr−/−, C1qa.Ldlr−/−, sIgM.Ldlr−/− and 
C1qa.sIgM.Ldlr−/− mice aged 22 weeks. 
 
 
Mouse genotype Diet n Final body 
weight (g) 
Total cholesterol 
(mmol/L) 
Total triglycerides 
(mmol/L) 
Ldlr−/− LF 12 22.4±0.43 7.48±0.44 1.58±0.22 
C1qa.Ldlr−/− LF 12 24.0±0.48 8.61±0.56 1.40±0.15 
sIgM.Ldlr−/− LF 14 24.0±0.62 8.61±0.65 1.67±0.16 
C1qa.sIgM.Ldlr−/− LF 10 24.4±0.40 7.80±0.77 1.17±0.15 
Ldlr−/− HF 12 25.7±1.05 39.6±1.34 4.63±0.45 
C1qa.Ldlr−/− HF 15 25.3±0.48 46.4±2.60 6.02±0.62 
sIgM.Ldlr−/− HF 15 23.7±0.55 40.7±2.05 4.61±0.34 
C1qa.sIgM.Ldlr−/− HF 9 23.8±0.55 44.8±2.18 4.74±0.61 
 
 
LF= low fat diet, HF= high fat diet. Values are expressed as mean±SEM. Differences 
between groups were not significant on either diet (statistical analysis by one-way ANOVA). 
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Supplemental Figure 1. Testing of the specificity of secondary antibody (alkaline 
phosphatase-conjugated polyclonal goat anti-mouse IgG2a) for mouse IgG2a and IgG2c
Graph shows the testing of the secondary antibody (alkaline phosphatase-conjugated goat 
anti-mouse IgG2a, Southern biotech cat. 1080-40) and its specificity for mouse IgG2a and 
IgG2c. The binding of 1080-40 antibody to both commercial IgG2a standard and IgG2c 
reference serum of known concentrations is demonstrated, showing that this particular batch 
of goat anti-mouse IgG2a antibody has similar specificity for both IgG2a and IgG2c below 
optical densities of ~1.0 for this ELISA setup. According to the manufacturer Southern 
Biotech, some batches of the 1080-40 antibody recognise both mouse IgG2a and IgG2c. 
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